Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting
The presence and severity of upper gastrointestinal mucosal lesions have not been evaluated using esophagogastroduodenoscopy (EGD) in patients receiving ticagrelor plus aspirin or alone after myocardial revascularization. Eighty-eight (38.1%) patients had a positive 13 C urea breath testing after 1 year of treatment after CABG. Severe upper gastrointestinal lesions were more frequently observed in patients treated with ticgrelor plus aspirin and aspirin monotherapy. Prophylactic use of PPIs migh
